Author

Jessica Minkue Mi Edou

Observed names: J. Minkue, J. Minkue Mi Edou, J.M.M. Edou, Jessica Minkue

Institution: Sanofi (Belgium)

Observed institutions: Ablynx (Belgium), Sanofi (Belgium)

ORCID: 0000-0003-3520-4882

Observed ORCID: 0000-0003-3520-4882

OpenAlex ID: A5010967142

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

2021 · Flora Peyvandi, Spero Cataland, et al. · Blood Advances · 88

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

2019 · Paul Knoebl, Spero Cataland, et al. · Journal of Thrombosis and Haemostasis · 72

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study

2022 · Marie Scully, Javier de la Rubia, et al. · Journal of Thrombosis and Haemostasis · 42

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

2018 · Flora Peyvandi, Spero R Cataland, et al. · Blood · 5

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

2018 · Paul Knöbl, Marie Scully, et al. · Blood · 5

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

2021 · Marie Scully, Javier de la Rubia, et al. · Blood · 4

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

2018 · Johanna A. Kremer Hovinga, Marie Scully, et al. · Blood · 4

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

2018 · Spero R Cataland, Marie Scully, et al. · Blood · 4

Integrated Efficacy Results From the Phase 2 and Phase 3 Studies With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

2021 · Flora Peyvandi, Spero Cataland, et al. · Hematology Transfusion and Cell Therapy · 2

Safety Results Normalized to Time of Exposure during the Phase 3 HERCULES Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

2019 · J.A. Kremer, M. Scully, et al. · Hämostaseologie · 2

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

2020 · L. Kaynar, P. Coppo, et al. · Hematology Transfusion and Cell Therapy · 1

Long-term Outcomes of Patients Treated With Caplacizumab for Immune-mediated Thrombotic Thrombocytopenic Purpura (ittp): the Post-hercules Study

2022 · Özgür Pektaş, Marie Scully, et al. · Hematology Transfusion and Cell Therapy

Outcomes of Patients With Worsening Acquired Thrombotic Thrombocytopenic Purpura (ttp) Despite Daily Therapeutic Plasma Exchange in the Phase 3 Hercules Trial

2020 · M. Scully, J.L. Rubia, et al. · Hematology Transfusion and Cell Therapy

Risk Factors and Manageability of the Mucocutaneous Bleeding Profile Observed in aTTP Patients Treated with Caplacizumab during the Phase III HERCULES Study

2019 · S. Cataland, M. Scully, et al. · Hämostaseologie

Safety Results Normalized to Time of Exposure during the Phase 3 HERCULES Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

2019 · J.A. Kremer, M. Scully, et al. · Hämostaseologie

Works count: 15

Citation count: 229

H-index: 5

I10-index: 3